Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389900 | 1.00 | AOC3 (0.48) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| SCHEMBL550790 | 1.00 | AOC3 (0.48) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| SCHEMBL550791 | 1.00 | AOC3 (0.48) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| SCHEMBL27825950 | 0.91 | TDP1 (0.50) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| SCHEMBL5873439 | 0.91 | TDP1 (0.50) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| SCHEMBL4077892 | 0.91 | TDP1 (0.50) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| SCHEMBL30801376 | 0.91 | SLC6A2 (0.54) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| SCHEMBL117950 | 0.91 | SLC6A2 (0.54) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| Alcohol SCHEMBL28032136 | 0.86 | AOC3 (0.46) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 | |
| Bicarbonate SCHEMBL27926290 | 0.84 | SLC6A2 (0.48) | AOC3ALDH1A1KDM4ESLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945651-B1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INST CANCER RES (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8334408-B2 | Analogs of alpha galactosylceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH | 2012-10-25 | — | — | US | disclosed |
| US-8188313-B2 | Analogs of alpha galactosylceramide and uses thereof | THE UNIVERSITY OF BIRMINGHAM (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | CERUNDOLO VINCENZO (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8039670-B2 | Analogs of alpha galactosyceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2009-09-24 | — | — | US | disclosed |
| EP-1945651-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | The Ludwig Institute for Cancer Research (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007050668-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | SGMS1, CERS2, SGMS2 | AOC3 829/4885ALDH1A1 1362/4885KDM4E 3311/4885 |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, CD69, GALC | AOC3 3588/4885ALDH1A1 2446/4885KDM4E 3645/4885 |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, GALC, CD69 | AOC3 3561/4885ALDH1A1 2622/4885KDM4E 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.